US DMF Filing for API Makers: First-Time Filer Guide
A US Drug Master File (DMF) is not an FDA approval -- it is a confidential reference document that FDA reviews only when an IND, NDA, or ANDA cites it. For API suppliers supporting generic drugs, Type II API DMF is the only category subject to GDUFA fees ($102,584 FY2026). The DMF fee is paid when the DMF is first referenced in an ANDA or when the holder requests completeness assessment (CA), not at submission. Critical infrastructure includes: site registration with FEI, US agent designation, pre-assigned DMF number, ESG NextGen account, eCTD publishing capability, and environmental assessment. After submission, administrative review (2 to 3 weeks) yields a DMF number; CA (60 calendar days after fee payment) yields "Available for Reference" status. Ongoing obligations: annual reports, change notifications to all authorized parties, and authorization list maintenance. US DMF filing success depends on understanding these three stages.
Why US DMF Filing Trips Up First-Timers
An API manufacturer ships its first US order. The customer says "you need a DMF." The manufacturer translates its Chinese NMPA dossier into English, submits it, gets a DMF number three months later, and thinks it's done. Six months later the customer's ANDA receives a complete response letter -- the DMF failed completeness assessment. The data quality wasn't the problem; the filer didn't understand the three DMF stages, when fees trigger, or what "Available for Reference" actually means. This guide walks through the practical realities of US DMF filing that regulatory consultants often assume you already know.
DMF Fundamentals -- What It Is and Isn't
DMF Is Not a Certificate
21 CFR 314.420(a) states: FDA does not independently review DMFs, nor approve or disapprove them. FDA reviews DMF content only in the context of a referencing application (IND, NDA, ANDA). A DMF number means only that FDA received and logged the submission. The commercially meaningful status is "Available for Reference" -- passed completeness assessment and listed as referenceable. Customers screen suppliers for this status, not for a DMF number.
Five DMF Types
Type | Content | GDUFA DMF Fee |
Type II | Drug substance, intermediates, materials used in preparation, or drug product | Yes (API only) |
Type III | Packaging material | No |
Type IV | Excipient, colorant, flavor, essence, and preparation materials | No |
Type V | FDA-accepted reference information | No |
Type V requires a letter of intent to Drug Master File Staff before submission. For API suppliers supporting ANDAs, Type II API DMF is the only relevant category -- and the only one triggering GDUFA DMF fees.
Six Infrastructure Prerequisites -- Before You Submit
Missing any of these blocks submission. None relates to technical content quality.
1. Site Registration and FEI
Every manufacturing site must be registered in FDA's establishment registration system and have a Facility Establishment Identifier (FEI). Foreign sites must designate a US Agent. Form FDA 3938 has separate fields for holder and US agent -- both must be complete.
2. Pre-assigned DMF Number
Request a pre-assigned application number from CDER (CBER uses cberrims@fda.hhs.gov) before submission. This number goes on the cover letter and Form 3938.
3. ESG NextGen Account
Submit via FDA's Unified Submission Portal. Accounts inactive for 60 days auto-disable. Log in before submission season to reactivate.
4. eCTD Publishing Capability
DMFs must be eCTD format, transmitted via ESG. CDER supports eCTD v3.2.2 and v4.0. No PDF submissions. If you lack publishing tools, outsource -- do not force PDF into eCTD wrapper.
5. eCTD Structure
Module 1: Form 3938, cover letter, Letters of Authorization (LOAs). Technical content in Module 3.2.S (full suite). Do not skip the 2.3.S Quality Overall Summary -- it is expected.
6. Environmental Assessment
Include a categorical exclusion statement per 21 CFR 25.31, citing the specific provision and declaring no extraordinary circumstances. Including this upfront avoids a deficiency letter later.
Technical Content -- Where Reviewers Focus
Starting Material Justification
Apply ICH Q11 rationale for starting material selection. FDA's threshold for "which synthetic step enters GMP" is often earlier than China's NMPA expectation. Insufficient justification triggers requests to move the starting material earlier in the synthesis.
Process Description Consistency with Commercial Batches
The submitted process description must align with actual master batch records -- not the idealized R&D version. Discrepancies between filing and commercial manufacturing are a top deficiency.
Impurity Classification -- Four Separate Frameworks
Impurity Class | Guideline | Key Logic |
Organic impurities | ICH Q3A | Reporting, identification, qualification thresholds |
Mutagenic impurities | ICH M7 | Classification, control options, purge factor calculation |
Elemental impurities | ICH Q3D | PDE-based limits, risk assessment |
Residual solvents | ICH Q3C | Class 1/2/3, concentration limits |
Mixing these frameworks in one section confuses reviewers. Address each separately with its own logic.
Polymorphism and Particle Size
If solid-state form affects drug product performance (dissolution, bioavailability, stability), 3.2.S.1.3 and 3.2.S.3.1 must define control strategy with analytical methods. "No polymorphs known" is not acceptable without supporting data.
Stability Data
Provide ICH Q1A(R2) data: long-term, accelerated, and intermediate (if applicable). Propose a retest period with post-approval commitments. Bracketing and matrixing designs must be justified.
Sterile API
Requires full sterilization or aseptic process validation data -- a separate regulatory package.
Fees -- Timing, Amount, and Cash Flow
FY2026 Fee Schedule (October 1, 2025 to September 30, 2026)
Fee | Amount (USD) | Payer | Trigger |
DMF fee | $102,584 | Type II API DMF holder | First ANDA reference via initial LOA, or holder requests first CA -- whichever occurs first |
API facility fee (foreign) | $58,549 | Site owner | Annual, due October 1 or first business day after appropriations act |
API facility fee (domestic) | $43,549 | Site owner | Same as above |
ANDA fee | $358,247 | ANDA applicant | At ANDA submission |
Three Cash-Flow Decisions
1. DMF fee is not due at submission. Administrative review and DMF number assignment are fee-independent. Submit, get the number, then pay when the customer's ANDA references the DMF via LOA or when you proactively request CA. It is a one-time fee -- subsequent ANDA references incur no additional DMF fee. Common mistake: paying early, then the customer's project cancels -- no refund.
2. Facility fee is a separate, recurring obligation with severe consequences. Once a DMF is referenced by a pending or approved ANDA, the API facility must self-identify annually (May 1 to June 1) and pay the annual facility fee. Import Alert 66-76: facilities that fail to self-identify or pay produce API and drug products deemed misbranded, subject to refusal of admission. This is not a review delay -- it blocks product entry.
3. Type II DMF supporting NDA does not pay GDUFA DMF fee. NDA sponsors pay PDUFA fees. Confirm whether your customer files ANDA or NDA before quoting or budgeting.
Hidden costs: US agent annual fees, eCTD publishing, translation/medical writing, GMP gap remediation, FDA inspection readiness. For first-timers, these often equal or exceed official fees. US DMF filing budgets must account for these hidden costs.
Timeline -- How Long Each Stage Takes
Phase | Duration | Key Milestone |
T-6 to T-3 months | Infrastructure build, dossier writing, eCTD publishing | Ready to submit |
T0 | Submission via ESG | Submission date |
T0 + 2 to 3 weeks | Administrative review | Acknowledgement Letter with DMF number; status to Active (A) |
After fee payment | Completeness assessment (CA) | 90% of Type II API DMFs complete CA within 60 calendar days; pass to "Available for Reference" |
Customer ANDA submission | Customer places LOA copy in M1.4.2 | DMF enters technical review; pace follows ANDA |
During review | Deficiencies communicated via applicant or directly to holder | Response as amendment via ESG; Form 3938: Response to Deficiency |
Accelerated Path: DMF Prior Assessment
Since October 2024, Type II API DMF holders may request prior assessment 6 months before customer's ANDA submission, per FDA's "Review of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA." Requirements:
- At least one LOA with pre-assigned ANDA number
- References the Orange Book RLD (required for original ANDA support)
- Proof of GDUFA DMF fee payment
Value: critical for first-generic timing. Cost: fee paid early, and each API gets only one prior assessment request.
Three Ongoing Obligations After "Available for Reference"
1. Annual Report
Due on the original submission anniversary. Even if nothing changed, submit a "content remains current" statement. Long-term non-updating delays referencing application reviews; FDA may initiate closure.
2. Change Notification -- Every Authorized Party
21 CFR 314.420(c): "the holder shall notify in writing, each person authorized to reference that information." Any change to process, site, or specifications requires written notification to every LOA holder -- not just the major customer.
3. Authorization List Maintenance
314.420(d) requires the DMF to contain a complete current list of all authorized persons and their authorized scope. Product-specific authorizations must include product name and application number.
Seven Pitfalls That Catch First-Timers
- Translating Chinese NMPA dossier directly. Structure, detail level, and justification logic differ -- especially starting material rationale and impurity classification.
- Equating DMF number with "approved." Customers need "Available for Reference" (CA passed).
- Missing facility fee and self-identification. Result: product held at border as misbranded, not a review issue.
- Notifying only one customer of changes. All LOA holders must receive written notice.
- eCTD technical validation failure. Submission rejected, DMF number not issued, month lost.
- Providing DMF number but no LOA, or customer omits LOA in M1.4.2. Equals no reference.
- Bundling DMF fee and facility fee in quotes, or not knowing NDA-supported DMFs avoid GDUFA DMF fee.
Counterintuitive Truths
- The technical content is rarely the blocker. The three non-technical pillars -- submission infrastructure, fee timing, ongoing obligations -- cause most first-time failures.
- Paying the DMF fee early creates risk, not readiness. If the customer's project dies, the fee is gone. Wait for the LOA trigger.
- Facility fee non-payment stops trade, not review. Misbranded status means physical goods cannot enter the US. This is a supply chain event, not a regulatory timeline.
- One prior assessment per API. Use it strategically for first-generic windows; don't burn it on a backup program.
Practical Checklist for First-Time Filers
- Confirm customer files ANDA (Type II DMF fee applies) vs NDA (no GDUFA DMF fee)
- Register all manufacturing sites; obtain FEI; designate US agent
- Request pre-assigned DMF number from CDER
- Set up ESG NextGen account; test login
- Secure eCTD publishing (v3.2.2 or v4.0) -- in-house or qualified vendor
- Build Module 3.2.S per CTD; include 2.3.S Quality Overall Summary
- Write categorical exclusion for environmental assessment
- Prepare Form 3938 with holder and US agent fields complete
- Draft LOA template for customer use
- Submit DMF; await administrative review (2 to 3 weeks) for DMF number
- Track customer's ANDA timeline; pay DMF fee when LOA received or proactively request CA
- After CA pass: monitor "Available for Reference" status
- Calendar annual report (submission anniversary)
- Calendar facility fee self-identification (May 1 to June 1 annually)
- Build change notification workflow: every change to written notice to all LOA holders
- Maintain authorization list in DMF Module 1
Limitations
This guide covers Type II API DMF filing for ANDA support under current GDUFA III framework (FY2026 fees, 2024 prior assessment pathway). It does not address Type III, IV, V DMFs; CBER-regulated products; API for clinical trials only (IND reference); or post-approval changes requiring supplement vs. amendment determination. Fee amounts update annually via Federal Register. Regulatory requirements evolve -- verify current guidance at time of filing. This article provides a procedural framework, not legal advice.
Bottom Line
US DMF filing succeeds on three non-technical disciplines: submission infrastructure ready before day one, fee payment timed to customer's ANDA not your submission date, and ongoing obligations (annual report, universal change notification, authorization list) built into quality systems. The technical dossier matters -- but it only gets reviewed after the infrastructure and fee gates pass. First-time filers: post this checklist on the wall. It beats hiring two more consultants. US DMF filing is a process, not a one-time event.
FAQ
What is the difference between a DMF number and "Available for Reference" status?
A DMF number means FDA received and logged the submission (administrative review passed). "Available for Reference" means the DMF passed completeness assessment (CA) -- 60 calendar days after fee payment -- and is listed as a referenceable file. Only the latter allows ANDA reliance.
When do I pay the GDUFA DMF fee?
Not at submission. Pay when: (1) a customer's ANDA references your DMF via an initial LOA, or (2) you proactively request completeness assessment. Whichever occurs first triggers the one-time $102,584 fee (FY2026).
Do I pay the DMF fee for each customer that references my DMF?
No. The DMF fee is a one-time payment of $102,584 (FY2026). Once paid, subsequent ANDA references by other customers incur no additional DMF fee. The facility fee, however, is annual and separate -- it applies once your DMF is referenced by any pending or approved ANDA.
What happens if I don't pay the API facility fee?
Once your DMF is referenced by a pending or approved ANDA, your facility must self-identify (May 1 to June 1) and pay the annual facility fee. Non-payment renders your API and any drug product containing it misbranded under Import Alert 66-76 -- subject to refusal of admission at the US border.
Does a Type II DMF supporting an NDA pay the GDUFA DMF fee?
No. NDA sponsors pay PDUFA fees. Only Type II API DMFs referenced in ANDAs trigger the GDUFA DMF fee. Confirm your customer's application type before budgeting.
What is a Letter of Authorization (LOA) and where does the customer place it?
An LOA authorizes FDA to review your DMF in the context of the customer's application. The customer must place a copy in Module 1.4.2 of their eCTD submission. Without the LOA in M1.4.2, the DMF is not considered referenced.
Can I submit a DMF in PDF format?
No. DMFs must be submitted in eCTD format (v3.2.2 or v4.0) transmitted via the ESG NextGen portal. PDF submissions are rejected at technical validation and will not receive a DMF number. If you lack eCTD publishing capability, engage a qualified vendor rather than attempting to wrap PDFs in eCTD structure.
What is DMF Prior Assessment and when should I use it?
Available since October 2024: Type II API DMF holders may request FDA to review the DMF up to 6 months before the customer's ANDA submission. Requirements: LOA with pre-assigned ANDA number, Orange Book RLD reference, proof of DMF fee payment. Each API gets only one prior assessment. Use for first-generic timing-critical programs.
What must be in the annual report?
Due on the original submission anniversary. If no changes: a statement that "the content of the DMF remains current." If changes: describe all changes since last annual report. Failure to file delays referencing application reviews and may trigger FDA closure proceedings.
Do I need to notify all customers when I make a change to my DMF?
Yes. 21 CFR 314.420(c) requires written notification to each person authorized to reference the DMF -- not just the primary customer. Any change to process, site, or specifications triggers this obligation.
What is the authorization list and where is it kept?
314.420(d) requires the DMF to contain a complete list of all currently authorized persons and their authorized scope. Product-specific authorizations must include product name and application number. Maintain this in Module 1 of the DMF.
How long does completeness assessment take?
The GDUFA performance goal is that 90% of Type II API DMF first-cycle completeness assessments are completed within 60 calendar days of fee payment. This timeline starts after the DMF fee is paid and FDA initiates the completeness assessment review.
What if my eCTD fails technical validation?
The submission is rejected, no DMF number is issued, and you must fix the eCTD errors and resubmit. Typical loss: 2 to 4 weeks. Validate eCTD structure before submission using FDA's eCTD validation tools.
Can I use my Chinese NMPA stability data directly in the DMF?
Data can be used but must be presented per ICH Q1A(R2) format and labeling. The DMF's stability section follows CTD 3.2.S.7 structure. Chinese data packages often need reformatting and supplemental commitments (retest period, post-approval protocol).
What is a US Agent and why do I need one?
Foreign establishments must designate a US Agent (21 CFR 314.420). The agent receives FDA communications, schedules inspections, and serves as the domestic contact. Form 3938 has dedicated fields for both holder and US agent information.